Gefapixant + Placebo + Naproxen

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Endometriosis-related Pain

Conditions

Endometriosis-related Pain

Trial Timeline

Sep 11, 2018 → Jun 30, 2020

NCT ID

NCT03654326

About Gefapixant + Placebo + Naproxen

Gefapixant + Placebo + Naproxen is a phase 2 stage product being developed by Merck for Endometriosis-related Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT03654326. Target conditions include Endometriosis-related Pain.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03654326	Phase 2	Completed	Sep 11, 2018	Jun 30, 2020	Endometriosis-related Pain